The limited activity-selectivity of Sorafenib (BAY 43–9006), the first RAF kinase inhibitor, for the RAF kinases [134–137] in tumours with BRAF mutation prompted the development of second-generation RAF inhibitors with greater selectivity for mutant BRAF. Here, RAF1 is linked to neoplasm.